Development of a New FR-Targeting Agent 99mTc-HYNFA with Improved Imaging Contrast and Comparison of Multimerization
and/or PEGylation Strategies for Radio-Folate Modification
posted on 2017-10-02, 00:00authored byZhide Guo, Linyi You, Changrong Shi, Manli Song, Mengna Gao, Duo Xu, Chenyu Peng, Rongqiang Zhuang, Ting Liu, Xinhui Su, Jin Du, Xianzhong Zhang
This study aims to develop a new
folate receptor (FR)-targeting
agent for SPECT imaging with improved contrast and evaluate the modification
strategies of multimerization and/or PEGylation in the development
of new radio-folates. A series of novel folate derivatives have been
synthesized and radiolabeled with 99mTc using tricine and
TPPTS as coligands. To better investigate their pharmacokinetics,
cell uptake, biodistribution, and microSPECT/CT imaging were evaluated.
Four radioligands displayed high KB cell uptake after incubation for
2 and 4 h. Presaturated with excess folic acid (FA) resulted in a
significant blocking effect in KB cells, indicating specificity of
these radioligands toward FR. Biodistribution and microSPECT imaging
studies in KB tumor-bearing mice showed that the folate conjugate 99mTc-HYNFA with poly(ethylene glycol) (PEG) and triazole linkage
displayed the highest tumor uptake (16.30 ± 2.01 %ID/g at 2 h
p.i. and 14.9 ± 0.62 %ID/g at 4 h p.i. in mice biodistribution)
and best imaging contrast, indicating promising application prospect.
More interestingly, the in vivo performance of this monomeric 99mTc-HYNFA was much better than that of FA multimers and non-PEGylated
monomers, suggesting that multimerization may not be a feasible method
for the design of radio-folates. PEG linkage rather than FA multimerization
should be taken into consideration in the development of folate-based
radiopharmaceuticals in the future.